Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy

Baang, Ji Hoon

doi:10.1001/jama.2015.1438

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the increasing awareness of HBV reactivation during chemotherapy in cancer patients, incipient screening and antiviral prophylaxis have been accepted gradually in clinical practices (Ludwig, Cohen, Papanicolaou, & Seo, 2015). Recent studies concentrate mostly on antiviral prophylaxis in the context of hematologic malignancies such as lymphoma (Baang, 2015;Cerchione et al, 2014;Lu et al, 2015), but when it comes to solid tumours, antiviral prophylaxis is not standardied, thus remains controversial. Currently, newer NAs for antiviral treatment have been widely researched and applied, such as entecavir, adefovir, telbivudine and tenofovir.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, newer NAs for antiviral treatment have been widely researched and applied, such as entecavir, adefovir, telbivudine and tenofovir. Recent studies concentrate mostly on antiviral prophylaxis in the context of hematologic malignancies such as lymphoma (Baang, 2015;Cerchione et al, 2014;Lu et al, 2015), but when it comes to solid tumours, antiviral prophylaxis is not standardied, thus remains controversial. While a few meta-analyses (Hicks LK et al, 2016;Paul et al, 2016) have investigated the effectiveness of prophylactic NAs prior to chemotherapy in the setting of solid tumours, none of them managed to make a solo probe into the prophylactic effects of lamivudine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis

Dai

Arshad

et al. 2017

Eur J Cancer Care

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation is a remarkable risk during the chemotherapy for solid tumour patients. Nucleos(t)ide analogues (NAs) are recommended as prophylaxis for the reactivation of HBV infection in some cancer patients prior to systemic chemotherapy. Therefore, we performed a meta-analysis aiming to determine the efficacy of prophylactic lamivudine on prevention of HBV reactivation and its related negative outcomes among solid tumour patients with chronic HBV infection receiving systemic chemotherapy. The primary outcome was HBV reactivation, and the secondary outcomes were HBV-related hepatitis, chemotherapy disruption, mortality and tyrosine-methio-nine-aspartate-aspartate (YMDD) mutations. Twelve original researches involving 1,101 patients were analysed in this study. The relative risk of HBV reactivation in patients with lamivudine prophylaxis was significantly lower than that without prophylaxis (RR = 0.17, 95% CL: 0.10-0.29, p < .00001). Lamivudine prophylaxis reduced the relative risk of hepatitis (p < .00001), chemotherapy disruptions (p = .01) and mortality (p = .08) due to HBV reactivation. Lamivudine prophylaxis is effective in reducing HBV reactivation and its related negative outcomes, such as hepatitis and chemotherapy disruption and mortality among chemotherapeutic solid tumour patients with chronic HBV infection. Future studies should lay more emphasis on the early HBV screening, mode of treatment and duration of NAs prophylaxis among solid tumour patients receiving chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis

Dai

Arshad

et al. 2017

Eur J Cancer Care

View full text Add to dashboard Cite

show abstract

Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations

Bessone¹,

Dirchwolf²

2016

WJH

View full text Add to dashboard Cite

The proportion of hepatitis B virus (HBV) previously exposed patients who receive immunosuppressive treatment is usually very small. However, if these individuals are exposed to potent immunosuppressive compounds, the risk of HBV reactivation (HBVr) increases with the presence of hepatitis B surface antigen (HBsAg) in the serum. Chronic HBsAg carriers have a higher risk than those who have a total IgG anticore as the only marker of resolved/occult HBV disease. The loss of immune control in these patients may results in the reactivation of HBV replication within hepatocytes. Upon reconstitution of the immune system, infected hepatocytes are once again targeted and damaged by immune surveillance in an effort to clear the virus. There are different virological scenarios, and a wide spectrum of associated drugs with specific and stratified risk for the development of HBVr. Some of this agents can trigger a severe degree of hepatocellular damage, including hepatitis, acute liver failure, and even death despite employment of effective antiviral therapies. Currently, HBVr incidence seems to be increasing around the world; a fact mainly related to the incessant appearance of more powerful immunosuppressive drugs launched to the market. Moreover, there is no consensus on the length of prophylactic treatment before the patients are treated with immunosuppressive therapy, and for how long this therapy should be extended once treatment is completed. Therefore, this review article will focus on when to treat, when to monitor, what patients should receive HBV therapy, and what drugs should be selected for each scenario. Lastly, we will update the definition, risk factors, screening, and treatment recommendations based on both current and different HBV management guidelines.

show abstract

Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy

Cited by 2 publications

References 9 publications

Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis

Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis

Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations

Contact Info

Product

Resources

About